Loading...
•
Sep 30
Autolus Q3 2025 Earnings Report
Autolus reported Q3 2025 results with $21.1M in revenue driven by AUCATZYL® and a net loss of $79.1M.
Key Takeaways
Autolus generated $21.1M in revenue in Q3 2025 from its commercial launch of AUCATZYL®, while expanding treatment access and progressing pipeline development. Despite a net loss, the company remains focused on expanding market share and advancing pivotal trials.
Generated $21.1M in net product revenue from AUCATZYL® in Q3 2025.
Reported a net loss of $79.1M and operating loss of $71.6M for the quarter.
Achieved target of 60 activated treatment centers in the U.S. ahead of schedule.
Expanded clinical pipeline with data in pediatric ALL and lupus nephritis and initiated MS trial.
Autolus
Autolus
Autolus Revenue by Segment
Autolus Revenue by Geographic Location
Revenue by Segment
AUCATZYL® Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Autolus aims to drive strong full-year sales, expand AUCATZYL's market share, and progress pivotal trials in pediatric ALL and lupus.
Positive Outlook
- Strong commercial and manufacturing performance supports guidance confidence.
- 60 U.S. treatment centers activated ahead of year-end target.
- Over 90% coverage of U.S. medical lives for AUCATZYL® achieved.
- Pivotal studies in pediatric ALL and lupus nephritis advancing.
- First patient dosed in MS trial, expanding future pipeline opportunities.
Challenges Ahead
- Q3 sales impacted by CMS reimbursement policy change in Q2.
- Continued operating and net losses reflect early commercialization stage.
- Cost of sales exceeds product revenue due to manufacturing scale-up.
- Cash balance decreased significantly from year-end 2024.
- No adjusted EPS figure disclosed, limiting clarity on profitability trajectory.